OncLive®, the leading digital provider of resources and information to oncology professionals, announces the 45 selected winners to attend the National Fellows Forum: Gyn-Onc on April 26-28 in Miami, Florida. This program provides an opportunity to gynecologic oncology fellows to share their research and data with industry leaders and peers.
The American Journal of Managed Care® (AJMC®), the leading peer-reviewed journal dedicated to topics in managed care, proudly announces Suzanne Delbanco, PhD, MPH, as the keynote speaker for this year’s spring Accountable Care Delivery Congress. The program will take place on May 11 at the Marriott Marquis San Diego.
CURE® magazine, the nation’s leading digital and print media enterprise focused on cancer patients, proudly announces Elizabeth Davis, RN, B.S.N., CPN, Jackie Miller, RN, B.S.N., OCN and Christine Stone, RN, M.S.N., OCN,as the three finalists for the 2018 Extraordinary Healer® Award for Oncology Nursing.
OncLive®, the leading provider of resources and information to oncology professionals, will host the latest State of the Science Summit™ on advanced non-small cell lung cancer on April 26 at the Sheraton La Jolla Hotel in La Jolla, California. The event will be chaired by Lyudmila Bazhenova, M.D., medical oncologist, professor of medicine, University of California, San Diego Health.
Targeted Oncology™, a print and digital resource that offers content and expert opinions on precision medicine in oncology, will launch the first Expert Perspective: Virtual Tumor Board on April 24. The Virtual Tumor Board is a video-editorial board discussion that features key opinion leaders from a specific oncological field. This first one will focus on chronic lymphocytic leukemia (CLL).
OncLive®, the leading digital provider of resources and information for oncology professionals, will presents its latest State of the Science Summit™ on hematologic malignancies on April 25 at Fairfield Inn and Suites by Marriott Charlotte Uptown in Charlotte, North Carolina. The event will be chaired by Saad Zafar Usmani, M.D., chief of Plasma Cell Disorders Program and Director of Clinical Research in Hematologic Malignancies, Atrium Health, Levine Cancer Institute.